Señales en vivo de 207940.KS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 02:30):

Stats
Volumen de hoy	0.00
Volumen promedio	62 854.00
Capitalización de mercado	55 871.59B
EPS	KRW0 ( 2024-04-24 )
Próxima fecha de ganancias	( KRW2 823.26 ) 2024-07-24
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW1 109.05 (0.14%)

Volumen Correlación

Largo: -0.05 (neutral)

Corto: 0.67 (moderate)

Signal:(54.163) Neutral

Samsung Biologics Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Samsung Biologics Correlación - Moneda/Commodity

0.59
( weak )

0.67
( moderate )

0.53
( weak )

-0.26
( neutral )

0.05
( neutral )

-0.12
( neutral )

Samsung Biologics Finanzas

Annual	2023
Ingresos:	KRW3 694.59B
Beneficio Bruto:	KRW1 802.76B (48.79 %)
EPS:	KRW12 050

FY	2023
Ingresos:	KRW3 694.59B
Beneficio Bruto:	KRW1 802.76B (48.79 %)
EPS:	KRW12 050

FY	2022
Ingresos:	KRW3 001.30B
Beneficio Bruto:	KRW1 468.45B (48.93 %)
EPS:	KRW11 442

FY	2021
Ingresos:	KRW1 568.01B
Beneficio Bruto:	KRW726.45B (46.33 %)
EPS:	KRW5 948.61

Financial Reports:

No articles found.

Samsung Biologics

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.